Searched for
GENERIC SEMAGLUTIDE
Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPCMarkets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target pricesDr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year...
- Dr Reddy’s aims to resume semaglutide supply by November after API fixDr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn SaldanhaGlenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from...
- Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killerIndia's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...
- Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetesSouth Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement die...
- Stocks in news: DMart, HCL Tech, ICICI Pru AMC, Dr Reddy’s, NTPC, IndiGoMarkets saw a strong rebound on Friday, driven by global cues and IT earnings. HCL Tech and ICICI Pru AMC will announce their first quarter...
- Dr Reddy’s pauses weight loss drug on quality fearsDr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the ...
- Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman SachsIndian pharmaceutical firms anticipate revenue increases in the first quarter of fiscal year twenty twenty six twenty seven. Profitability ...
- Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concernsDr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...
- Dr Reddy's flags quality issue in semaglutide batches, delays commercial suppliesDr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batche...
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...
- 'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
Load More
